The maker of a popular medicine for schizophrenia has notified doctors that it minimized potentially fatal safety risks and made misleading claims about the drug in promotional materials.
Janssen Pharmaceutic Products sent a two-page letter to the health care community this past week to clarify the risks of Risperdal, Carol Goodrich, a spokeswoman for the Johnson & Johnson subsidiary, said Saturday.
Dr. John Grohol is the CEO and founder of Psych Central. He is an author, researcher and expert in mental health online, and has been writing about online behavior, mental health and psychology issues -- as well as the intersection of technology and human behavior -- since 1992. Dr. Grohol sits on the editorial board of the journal Cyberpsychology, Behavior and Social Networking and is a founding board member and treasurer of the Society for Participatory Medicine.Like this author?
Catch up on other posts by John M. Grohol, PsyD (or subscribe to their feed).
Comments
This post currently has no comments. You can read the comments or leave your own thoughts on our new comments page.
Trackbacks
Last reviewed: By John M. Grohol, Psy.D. on 27 Jul 2004
Published on PsychCentral.com. All rights reserved.
APA Reference
Grohol, J. (2004). Drug Maker Acknowledges Misleading Claims. Psych Central. Retrieved on February 14, 2012, from http://psychcentral.com/blog/archives/2004/07/27/drug-maker-acknowledges-misleading-claims/
Grohol, J. (2004). Drug Maker Acknowledges Misleading Claims. Psych Central. Retrieved on February 14, 2012, from http://psychcentral.com/blog/archives/2004/07/27/drug-maker-acknowledges-misleading-claims/
